The discovery was made in a study on 23 patients.
Prof John Bell, lead researcher and from the University of Ottawa, said: “We are very excited because this is the first time in medical history that a viral therapy has been shown to consistently and selectively replicate in cancer tissue after intravenous infusion in humans.”
“Intravenous delivery is crucial for cancer treatment because it allows us to target tumors throughout the body as opposed to just those that we can directly inject.”
The treatment has only succeeded in preventing tumor development. Since the treatment is still at an experimental stage, patients received only one dose of JX-594.
Professor Bell acknowledges that research is still at an early stage, but believes that “viruses and other biological therapies could truly transform our approach for treating cancer.”